Drivers of tumorigenesis, and thus promising targets for therapeutic intervention, include recurrent hotspot mutations, fusions, and high-level (eg, >6-copy) focal amplifications.
Screening for actionable mutations facilitates the identification of patients who will benefit from targeted therapy.
Cancer genome research has revealed a number of actionable gene mutations. In this context, the most extensively investigated cancer type is lung adenocarcinoma (LADC), which represents the most common histological lung cancer subtype. LADC can be classi- RET and ROS1 fusions and BRAF mutations, in lung cancer patients. 6 As of December 2017, more than 5000 patients from 251 institutions had been enrolled. Patients who were positive for those oncogene alterations have been receiving (or received) targeted therapies using investigational drugs in clinical trials according to their gene alterations. 3, 6, 7 In the USA, the FDA approved the Oncomine Dx Target Test in June 2017 as a companion diagnostic test that simultaneously diagnoses alterations in three oncogenes, EGFR, BRAF, and ROS1, in lung cancer. Theoretically, this test can detect alterations of 23 "hotspot" panels (Table 1) to comprehensive genome-scale platforms. [13] [14] [15] [16] To ensure that the results can be applied in clinical practice, these NGS-based tests are carried out in Clinical Laboratory F I G U R E 1 Discovery of RET fusion and its translation to clinical oncology. RET fusion was discovered in 2012. 4 Nationwide screening for
RET and ROS1 fusions within the context of LC-SCRUM-Japan commenced in 2013. 6 LURET, an open-label, multicenter, phase II trial of vandetanib for RET fusion-positive lung cancer, also commenced in 2013. The LURET results were published in 2017. 3 TKI, tyrosine kinase inhibitor T A B L E 1 Next-generation sequencing-based tumor-profiling multiplex gene panels regimen that resulted in a decrease in disease progression (ie, by calculating the PFS ratio using the outcome of the patient's previous treatment history as a control) might be a way to address this issue.
The implementation of clinical sequencing in Japan presents several challenges. First, germline mutations can be detected as secondary findings in a small percentage of patients, as reported in a recent study of East Asians. 33 Implications in terms of informed consent, genetic counseling, and total care must therefore be taken into account. Second, many NGS-based gene panel tests, including the ones to examine cell-free DNA, such as the Guardant360 test, are expensive. 20 Japan operates a universal health-care system, in which patients are expected to pay 30% of the total cost of treatment. 34 The cost of clinical sequencing tests will therefore be a major economic issue for patients and the government. Ongoing discussion between representatives from industry, academia, and relevant regulatory bodies is warranted to facilitate the implementation of cancer genome medicine in Japan. Ikeda. The author is also grateful to many other staff at the National Cancer Center, Japan.
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